<p><strong>独家报道：</strong> 来自中国的威胁可能比大多数美国人意识到的更近——就坐落在他们的浴室柜子里。一份新报告警告称，美国对中国制造药品的依赖使国家处于脆弱状态，并指出了一个可能的解决方案：友岸外包，即学习依赖盟友而非对手。</p>
<p>美国以色列教育协会（USIEA）最近发布了一份报告，警告称 “外国国家正在对美国的药品柜子进行勒索。” 这其中包括中国，中国在美国医疗供应链中扮演着关键角色，因为 41% 的美国批准的活性药物成分（APIs）所需的关键采购材料（KSMs）完全来自中国。</p>
<p>此外，报告指出 “对于 679 种活性药物成分，至少有一种 KSM 的唯一供应商是中国，占所有活性药物成分的 37%”，这使得美国消费者面临严重风险。USIEA 认为，目前美国的医疗供应链将价格置于安全之上，相当于 “与坏演员玩俄罗斯轮盘赌”。</p>
<p><strong>供应链人工智能公司对美国对中国制造药品的依赖发出警报</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/03/931/523/woman-medication.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/03/931/523/woman-medication.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>美国以色列教育协会（USIEA）最近发布了一份报告，警告称 “外国国家正在对美国的药品柜子进行勒索。”（iStock / iStock）</p>
<p>“例如，我们在美国使用的药品中，90% 以上按体积计算是仿制药，而这些药品绝大多数是在海外生产，主要来自中国和印度。如果中国某天因为政治原因决定停止向我们发送药品……我们将面临非常艰难的境地，因为我们真的没有足够的药品来拯救人们的生命，” 前 FDA 副专员及 USIEA 高级研究员彼得·皮茨告诉福克斯商业频道。</p>
<p>USIEA 报告指出，新冠疫情是美国药品供应链脆弱性的一个典型例子，以及对中国的依赖可能变得危险。在疫情期间，美国经历了对比剂的短缺，医疗专业人员使用比剂来提高 X 光、CT 扫描和 MRI 中器官、血管和组织的可见性。报告指出，2022 年，位于上海附近的一家大型比剂制造设施因新冠封锁而关闭，导致美国出现混乱。</p>
<p>“在国内，这导致了血管造影、灌注扫描和其他对中风评估、癌症诊断和其他紧急医疗护理至关重要的测试的急剧减少，” 报告中写道。“这家位于中国的工厂几乎提供了美国使用的所有比剂。很容易想象，类似的供应链危机可能会出现在糖尿病测试条或 ADHD 药物，或青霉素等药物上，都是出于地缘政治的目的。”</p>
<p>然而，这个问题早于疫情。USIEA 报告提到 2008 年发生的一起事件，当时来自中国的劣质抗凝剂导致 81 人死亡，785 人重伤。</p>
<p>FDA 对中国生产的洞察也有限且受到严格控制，这使得 USIEA 认为这是一个 “灾难的配方”。</p>
<p>正如报告所解释的，当检查员被要求提前通知设施时，“生产日志会被更改，工厂车间会被清理，过期的物资会被移动，许多关键区域的访问会受到限制。”</p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/pills.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/pills.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>Torasemid AL 高血压药片从 Fette GmbH 制造的 Fette Compacting 2090i 机器中出来，拍摄于 2014 年德国 Bad Vilbel 的 Stada Arzneimittel AG 制药厂。（Krisztian Bocsi/Bloomberg / Getty Images）</p>
<p><strong>特朗普高级顾问表示新关税旨在结束中国对美国供应链的控制</strong></p>
<p>该组织提出了一项已经在华盛顿获得一些关注的解决方案——建立 FDA 亚伯拉罕协议办公室。报告将该办公室描述为 “区域监管使命”，将作为 “FDA 的前方部署延伸”，有三个主要优先事项：经济安全、公共健康和外交领导。</p>
<p>根据报告，FDA 亚伯拉罕协议办公室的目的是 “制度化友岸外包，使美国能够通过可信的合作伙伴多样化关键药品的供应链，同时保持 FDA 的 ‘黄金标准’ 监管。” 这将使美国能够将其依赖从风险较高的国家（如中国）转向更友好的国家（如以色列、阿联酋、巴林和摩洛哥）。</p>
<p>一项已经在众议院通过的两党法案中包含了创建 FDA 亚伯拉罕协议办公室的条款。该法案被称为 H.R.1262，或 “米凯拉·内隆给孩子们一个机会法案”，由德克萨斯州众议员迈克尔·麦考尔于 2 月份提出，并得到了两党共同发起的支持。根据该立法，该办公室不会批准药品，而是作为 FDA 与亚伯拉罕协议国家制造商之间的协调者。</p>
<p>USIEA 认为，亚伯拉罕协议国家可以成为 “共享监管标准和政治一致性的可信合作伙伴”。</p>
<p>“亚伯拉罕协议国家已经决定，他们正在展望 21 世纪……因此，这为扩展到一个美国在这个领域基本上忽视的世界区域提供了机会，” USIEA 政策与战略运营主任 EJ Kimball 告诉福克斯商业频道。</p>
<p>然而，友岸外包战略既实用又政治，Kimball、Pitts 和 USIEA 认为，亚伯拉罕协议国家已经准备好满足美国的药品需求。</p>
<p>“[以色列和阿拉伯联合酋长国] 是两个非常稳定的实体，在多个领域高度先进，其中包括制药开发和制造，” 皮特斯说。“他们在这些领域的表现远超预期。”</p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/medicine-manufacturing-china.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/medicine-manufacturing-china.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>2023 年，在中国辽宁省沈阳的一家工厂，员工在生产线工作，生产咳嗽药物小青龙胶囊。(VCG/VCG via Getty Images / Getty Images)</p>
<p><strong>亚伯拉罕协议的设计者表示，这是他几十年来首次对中东感到乐观</strong></p>
<p>推动与亚伯拉罕协议国家扩大制药合作，不仅是为了确保美国的供应链；这也将使美国在应对中国影响力方面占得先机。金博尔警告称，中国一直在努力加深其在中东的存在。然而，他和皮特斯相信，通过增加与亚伯拉罕协议国家的关系，美国可以阻止中国的扩张。</p>
<p>“摩洛哥非常明确地告诉我们，他们希望与美国合作，而中国正在敲他们的门。他们确实与中国有一些合作，但他们理解这对他们构成的威胁，因此如果美国不在某个时刻去敲他们的门，最终中国会进来，因为当他们给你提供如此多的东西时，你只能说 ‘不’ 这么久，” 金博尔说。</p>
<p>皮特斯批评过去的美国政府 “对潜在国际伙伴冷淡”，没有考虑后果。然而，他相信美国仍然可以吸引那些转向中国的国家。</p>
<p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/hands-holding-pills.jpg/query-dGw9MSZ2ZT0x?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/hands-holding-pills.jpg/query-dGw9MSZ2ZT0x"/></p>
<p>在巴德维尔的制药制造商 STADA 总部，生产含有 “Grippostad” 药物的硬胶囊。(Boris Roessler/picture alliance via Getty Images / Getty Images)</p>
<p><strong>点击这里获取 FOX 商业新闻</strong></p>
<p>“只要我们张开双臂，表示我们希望与值得信赖的国家做生意，与那些重视高质量、不作弊、讲究公平的国家合作，与那些认识到技术进步价值的国家合作，出于非军事和地缘政治的原因，我们每次都能赢，而且大家都能受益，” 皮特斯说。</p>
<p>美国国际经济协会（USIEA）主张，将供应链转移到更友好的国家，例如亚伯拉罕协议国家，不仅是战略举措，更是保护国家安全的必要行为。正如报告所述，“在一个供应中断可能危及国家稳定与军事威胁同样严重的世界中，确保获得基本药物是一种主权行为。”</p>

<p>一份 USIEA 报告强调了美国因依赖中国制造的药品而面临的脆弱性，建议与以色列等盟友进行友好外包以降低风险。报告警告可能出现的供应链中断，引用了过去的事件和 COVID-19 疫情。它提倡设立 FDA 亚伯拉罕协议办公室，以多样化供应链并确保经济安全、公共健康和外交领导力。一项两党法案支持这一倡议</p>

<p><strong>EXCLUSIVE:</strong> The threat from China may be closer to home than most Americans realize — sitting in their bathroom cabinets. A new report warns that the U.S.'s dependence on Chinese-made drugs leaves the country vulnerable and points to a possible fix: friend-shoring, or learning to rely on allies rather than adversaries.</p>
<div class="lb-trans"><p><strong>独家报道：</strong> 来自中国的威胁可能比大多数美国人意识到的更近——就坐落在他们的浴室柜子里。一份新报告警告称，美国对中国制造药品的依赖使国家处于脆弱状态，并指出了一个可能的解决方案：友岸外包，即学习依赖盟友而非对手。</p>
</div><p>The U.S. Israel Education Association (USIEA) recently released a report warning that &#34;foreign nations are holding America’s medicine cabinets for ransom.&#34; This includes China, which plays a key role in the U.S. medical supply chain as 41% of Key Sourcing Materials (KSMs) used in U.S.-approved active pharmaceutical ingredients (APIs) are sole sourced from China.</p>
<div class="lb-trans"><p>美国以色列教育协会（USIEA）最近发布了一份报告，警告称 “外国国家正在对美国的药品柜子进行勒索。” 这其中包括中国，中国在美国医疗供应链中扮演着关键角色，因为 41% 的美国批准的活性药物成分（APIs）所需的关键采购材料（KSMs）完全来自中国。</p>
</div><p>Additionally, the report notes that &#34;China is the sole supplier of at least one KSM for 679 APIs, accounting for 37% of all APIs,&#34; which puts the American consumer at serious risk. USIEA argues that the current U.S. medical supply chain puts price before safety and the equivalent of &#34;playing Russian Roulette&#34; with bad actors.</p>
<div class="lb-trans"><p>此外，报告指出 “对于 679 种活性药物成分，至少有一种 KSM 的唯一供应商是中国，占所有活性药物成分的 37%”，这使得美国消费者面临严重风险。USIEA 认为，目前美国的医疗供应链将价格置于安全之上，相当于 “与坏演员玩俄罗斯轮盘赌”。</p>
</div><p><strong>SUPPLY CHAIN AI COMPANY SOUNDS THE ALARM OVER AMERICA'S RELIANCE ON CHINESE-MADE PHARMACEUTICALS</strong></p>
<div class="lb-trans"><p><strong>供应链人工智能公司对美国对中国制造药品的依赖发出警报</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/03/931/523/woman-medication.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2023/03/931/523/woman-medication.jpg?ve=1&amp;tl=1"/></p>
<p>The U.S. Israel Education Association (USIEA) recently released a report warning that &#34;foreign nations are holding America’s medicine cabinets for ransom.&#34; (iStock / iStock)</p>
<div class="lb-trans"><p>美国以色列教育协会（USIEA）最近发布了一份报告，警告称 “外国国家正在对美国的药品柜子进行勒索。”（iStock / iStock）</p>
</div><p>&#34;About 90-plus percent of the pharmaceuticals, for example, that we use here in the United States by volume are generic drugs, and they are overwhelmingly produced overseas, largely out of China and India. And if China decided one day to simply stop sending us pharmaceutical products because of political reasons... we'd be in very tough straits because we really would not have the pharmaceutical products we need to save people's lives,&#34; former FDA Associate Commissioner and USIEA Senior Fellow Peter Pitts told Fox Business.</p>
<div class="lb-trans"><p>“例如，我们在美国使用的药品中，90% 以上按体积计算是仿制药，而这些药品绝大多数是在海外生产，主要来自中国和印度。如果中国某天因为政治原因决定停止向我们发送药品……我们将面临非常艰难的境地，因为我们真的没有足够的药品来拯救人们的生命，” 前 FDA 副专员及 USIEA 高级研究员彼得·皮茨告诉福克斯商业频道。</p>
</div><p>The USIEA report points to the COVID-19 pandemic as a prime example of the vulnerabilities in the U.S. pharmaceutical supply chain and how its reliance on China could become dangerous. During the pandemic, the U.S. experienced a shortage of contrast agent, which is what medical professionals use to improve visibility of organs, blood vessels and tissues in X-rays, CT scans and MRIs. The report notes that in 2022, a large contrast agent manufacturing facility near Shanghai shut down due to a COVID lockdown, causing chaos in the U.S.</p>
<div class="lb-trans"><p>USIEA 报告指出，新冠疫情是美国药品供应链脆弱性的一个典型例子，以及对中国的依赖可能变得危险。在疫情期间，美国经历了对比剂的短缺，医疗专业人员使用比剂来提高 X 光、CT 扫描和 MRI 中器官、血管和组织的可见性。报告指出，2022 年，位于上海附近的一家大型比剂制造设施因新冠封锁而关闭，导致美国出现混乱。</p>
</div><p>&#34;Here at home, this resulted in radical decreases in angiograms, perfusion scans and other tests crucial for stroke assessments, cancer diagnoses, and other urgent medical care,&#34; the report reads. &#34;This one plant in China provides almost all the contrast agent used in the United States. It’s not hard to imagine similar supply chain crises for diabetes test strips or ADHD medications, or penicillin driven by geopolitical purposes.&#34;</p>
<div class="lb-trans"><p>“在国内，这导致了血管造影、灌注扫描和其他对中风评估、癌症诊断和其他紧急医疗护理至关重要的测试的急剧减少，” 报告中写道。“这家位于中国的工厂几乎提供了美国使用的所有比剂。很容易想象，类似的供应链危机可能会出现在糖尿病测试条或 ADHD 药物，或青霉素等药物上，都是出于地缘政治的目的。”</p>
</div><p>The issue, however, predates the pandemic. The USIEA report references an instance in 2008 when a substandard anticoagulant from China killed 81 people and left 785 severely injured.</p>
<div class="lb-trans"><p>然而，这个问题早于疫情。USIEA 报告提到 2008 年发生的一起事件，当时来自中国的劣质抗凝剂导致 81 人死亡，785 人重伤。</p>
</div><p>The FDA’s insight into Chinese production is also limited and heavily controlled, making for what the USIEA deems a &#34;recipe for disaster.&#34;</p>
<div class="lb-trans"><p>FDA 对中国生产的洞察也有限且受到严格控制，这使得 USIEA 认为这是一个 “灾难的配方”。</p>
</div><p>As the report explains, when inspectors are required to notify a facility ahead of time, &#34;manufacturing logs get altered, factory floors get cleaned, expired supplies get moved, and access to many key areas get restricted.&#34;</p>
<div class="lb-trans"><p>正如报告所解释的，当检查员被要求提前通知设施时，“生产日志会被更改，工厂车间会被清理，过期的物资会被移动，许多关键区域的访问会受到限制。”</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/pills.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/pills.jpg?ve=1&amp;tl=1"/></p>
<p>Torasemid AL high blood pressure tablets exit a Fette Compacting 2090i machine, manufactured by Fette GmbH, at the Stada Arzneimittel AG pharmaceutical factory in Bad Vilbel, Germany, in 2014. (Krisztian Bocsi/Bloomberg / Getty Images)</p>
<div class="lb-trans"><p>Torasemid AL 高血压药片从 Fette GmbH 制造的 Fette Compacting 2090i 机器中出来，拍摄于 2014 年德国 Bad Vilbel 的 Stada Arzneimittel AG 制药厂。（Krisztian Bocsi/Bloomberg / Getty Images）</p>
</div><p><strong>TRUMP SENIOR COUNSELOR SAYS NEW TARIFFS DESIGNED TO END CHINA’S GRIP ON US SUPPLY CHAIN</strong></p>
<div class="lb-trans"><p><strong>特朗普高级顾问表示新关税旨在结束中国对美国供应链的控制</strong></p>
</div><p>The organization put forward a solution that has already gotten some traction in Washington — the establishment of an FDA Abraham Accords Office. The report describes the office as a &#34;regional regulatory mission&#34; that would act as &#34;a forward-deployed extension of the FDA&#34; with three major priorities: economic security, public health and diplomatic leadership.</p>
<div class="lb-trans"><p>该组织提出了一项已经在华盛顿获得一些关注的解决方案——建立 FDA 亚伯拉罕协议办公室。报告将该办公室描述为 “区域监管使命”，将作为 “FDA 的前方部署延伸”，有三个主要优先事项：经济安全、公共健康和外交领导。</p>
</div><p>The purpose of the FDA Abraham Accords Office, according to the report, would be &#34;to institutionalize friend-shoring, enabling the U.S. to diversify supply chains for essential medicines through trusted partners while maintaining the FDA’s 'gold standard' for oversight.&#34; This would allow the U.S. to shift its reliance from riskier nations, such as China, to friendlier ones, such as Israel, the United Arab Emirates, Bahrain and Morocco.</p>
<div class="lb-trans"><p>根据报告，FDA 亚伯拉罕协议办公室的目的是 “制度化友岸外包，使美国能够通过可信的合作伙伴多样化关键药品的供应链，同时保持 FDA 的 ‘黄金标准’ 监管。” 这将使美国能够将其依赖从风险较高的国家（如中国）转向更友好的国家（如以色列、阿联酋、巴林和摩洛哥）。</p>
</div><p>A bipartisan bill that has already passed in the House has a provision for creating the FDA Abraham Accords Office. The bill, known as H.R.1262, or the &#34;Mikaela Naylon Give Kids a Chance Act,&#34; was introduced by Rep. Michael McCaul, R-Texas, in February and has co-sponsors from both parties. According to the legislation, the office would not be approving drugs, rather it would work as a coordinator between the FDA and manufacturers in the Abraham Accords nations.</p>
<div class="lb-trans"><p>一项已经在众议院通过的两党法案中包含了创建 FDA 亚伯拉罕协议办公室的条款。该法案被称为 H.R.1262，或 “米凯拉·内隆给孩子们一个机会法案”，由德克萨斯州众议员迈克尔·麦考尔于 2 月份提出，并得到了两党共同发起的支持。根据该立法，该办公室不会批准药品，而是作为 FDA 与亚伯拉罕协议国家制造商之间的协调者。</p>
</div><p>The USIEA argues that the Abraham Accords nations can be &#34;trusted partners who share regulatory standards and political alignment.&#34;</p>
<div class="lb-trans"><p>USIEA 认为，亚伯拉罕协议国家可以成为 “共享监管标准和政治一致性的可信合作伙伴”。</p>
</div><p>&#34;The Abraham Accords countries have made a decision that they are looking to the 21st century... So, it's provided this opportunity to expand into an area of the world that, quite frankly, the United States, especially in this space, had largely ignored,&#34; USIEA Director of Policy and Strategic Operations EJ Kimball told Fox Business.</p>
<div class="lb-trans"><p>“亚伯拉罕协议国家已经决定，他们正在展望 21 世纪……因此，这为扩展到一个美国在这个领域基本上忽视的世界区域提供了机会，” USIEA 政策与战略运营主任 EJ Kimball 告诉福克斯商业频道。</p>
</div><p>However, the friend-shoring strategy is as practical as it is political, as Kimball, Pitts and the USIEA argue that the Abraham Accords nations are ready to meet the U.S.'s pharmaceutical needs.</p>
<div class="lb-trans"><p>然而，友岸外包战略既实用又政治，Kimball、Pitts 和 USIEA 认为，亚伯拉罕协议国家已经准备好满足美国的药品需求。</p>
</div><p>&#34;[Israel and the United Arab Emirates] are two very stable entities that are highly advanced in a number of different areas, not the least of which are pharmaceutical development and manufacturing,&#34; Pitts said. &#34;They punch well above their weight in these spaces.&#34;</p>
<div class="lb-trans"><p>“[以色列和阿拉伯联合酋长国] 是两个非常稳定的实体，在多个领域高度先进，其中包括制药开发和制造，” 皮特斯说。“他们在这些领域的表现远超预期。”</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/medicine-manufacturing-china.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/medicine-manufacturing-china.jpg?ve=1&amp;tl=1"/></p>
<p>Employees work on the production line of Xiaoqinglong capsules, a cough medicine, at a factory in 2023 in Shenyang, Liaoning Province of China. (VCG/VCG via Getty Images / Getty Images)</p>
<div class="lb-trans"><p>2023 年，在中国辽宁省沈阳的一家工厂，员工在生产线工作，生产咳嗽药物小青龙胶囊。(VCG/VCG via Getty Images / Getty Images)</p>
</div><p><strong>ABRAHAM ACCORDS ARCHITECT SAYS IT’S THE FIRST TIME IN DECADES HE’S BEEN OPTIMISTIC ABOUT THE MIDDLE EAST</strong></p>
<div class="lb-trans"><p><strong>亚伯拉罕协议的设计者表示，这是他几十年来首次对中东感到乐观</strong></p>
</div><p>The push to expand pharmaceutical cooperation with the Abraham Accords nations is about more than securing America's supply chain; it would also allow the U.S. to get ahead of Chinese influence. Kimball warns that China has been hard at work trying to deepen its presence in the Middle East. However, he and Pitts believe that by adding to its Abraham Accords relationships, the U.S. can stop China in its tracks.</p>
<div class="lb-trans"><p>推动与亚伯拉罕协议国家扩大制药合作，不仅是为了确保美国的供应链；这也将使美国在应对中国影响力方面占得先机。金博尔警告称，中国一直在努力加深其在中东的存在。然而，他和皮特斯相信，通过增加与亚伯拉罕协议国家的关系，美国可以阻止中国的扩张。</p>
</div><p>&#34;Morocco was very clear to us that they want to work with the United States, and China is knocking on their door. And they do some work with China, but they understand the threat that it poses to them, and so if the United States doesn't come at some point to knock on their door as well, eventually China's going to come in because you can only say 'no' for so long when they're offering so much to you,&#34; Kimball said.</p>
<div class="lb-trans"><p>“摩洛哥非常明确地告诉我们，他们希望与美国合作，而中国正在敲他们的门。他们确实与中国有一些合作，但他们理解这对他们构成的威胁，因此如果美国不在某个时刻去敲他们的门，最终中国会进来，因为当他们给你提供如此多的东西时，你只能说 ‘不’ 这么久，” 金博尔说。</p>
</div><p>Pitts slammed past U.S. administrations for &#34;giving the cold shoulder&#34; to potential international partners without thinking about the consequences. However, he believes that the U.S. can still attract countries that have turned to China.</p>
<div class="lb-trans"><p>皮特斯批评过去的美国政府 “对潜在国际伙伴冷淡”，没有考虑后果。然而，他相信美国仍然可以吸引那些转向中国的国家。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/hands-holding-pills.jpg/query-dGw9MSZ2ZT0x" alt="" original-src="https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2025/12/931/523/hands-holding-pills.jpg?ve=1&amp;tl=1"/></p>
<p>Hard capsules containing the medicine &#34;Grippostad&#34; are produced at the headquarters of the pharmaceutical manufacturer STADA in Bad Vilbel. (Boris Roessler/picture alliance via Getty Images / Getty Images)</p>
<div class="lb-trans"><p>在巴德维尔的制药制造商 STADA 总部，生产含有 “Grippostad” 药物的硬胶囊。(Boris Roessler/picture alliance via Getty Images / Getty Images)</p>
</div><p><strong>GET FOX BUSINESS ON THE GO BY CLICKING</strong> <strong>HERE</strong></p>
<div class="lb-trans"><p><strong>点击这里获取 FOX 商业新闻</strong></p>
</div><p>&#34;As soon as we open up our arms and say we want to do business with countries that we trust, with countries that embrace high quality, with countries that don't cheat, with countries that play fair, with countries that recognize the value of technological advancement for reasons other than military and geopolitical posturing, you know, we win hands down every time, and everybody wins,&#34; Pitts said.</p>
<div class="lb-trans"><p>“只要我们张开双臂，表示我们希望与值得信赖的国家做生意，与那些重视高质量、不作弊、讲究公平的国家合作，与那些认识到技术进步价值的国家合作，出于非军事和地缘政治的原因，我们每次都能赢，而且大家都能受益，” 皮特斯说。</p>
</div><p>The USIEA asserts that moving the supply chain to friendlier nations, such as those in the Abraham Accords, is not just a strategic move but an essential act to protect national security. As the report puts it, &#34;In a world where supply disruptions can endanger national stability as much as military threats, ensuring access to essential medicines is an act of sovereignty.&#34;</p>
<div class="lb-trans"><p>美国国际经济协会（USIEA）主张，将供应链转移到更友好的国家，例如亚伯拉罕协议国家，不仅是战略举措，更是保护国家安全的必要行为。正如报告所述，“在一个供应中断可能危及国家稳定与军事威胁同样严重的世界中，确保获得基本药物是一种主权行为。”</p>
</div>

中国威胁美国的药品供应，报告指出盟友可能会反制这一威胁